[Clinic characteristics and prognosis in 102 non-small cell lung cancer patients less than 40 years old]

Zhongguo Fei Ai Za Zhi. 2013 Feb;16(2):73-7. doi: 10.3779/j.issn.1009-3419.2013.02.03.
[Article in Chinese]

Abstract

Background and objective: The incidence of young non-small cell lung cancer (NSCLC) annually increases. The aim of this study is to analyze the clinical pathological characteristics of young (less than 40 years old) NSCLC patients.

Methods: The data of 102 young NSCLC were retrospectively analyzed.

Results: Among the 102 patients, 43.1% were women and 29.4% were smokers. The male-to-female ratio was 1.32:1. The most frequent histologic type was adenocarcinoma (77.5%). Tumor differentiation was mostly poor (64.1%), and 87.8% had stages IIIb and IV diseases. The median recurrence time of 6 patients who had tumor resection was 13.5 months. The objective response rate (ORR) of 87 patients who received first-line chemotherapy was 46.0%, the disease control rate (DCR) was 79.3%, and the median time to progression (TTP) was 5.0 months. The ORR of 38 patients who received epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) therapy was 40.0%, with a DCR of 65.7% and a median TTP of 5.5 months. The DCR of 12 patients who received EGFR-TKI twice or more times was 66.7%, with a median TTP of 3.0 months.

Conclusions: The time from the first presenting symptom until diagnosis was usually long. The female proportion presented an upward trend and the correlation became attenuated between young NSCLC patients and smoking. Most of the young NSCLC patients had adenocarcinoma and poor tumor differentiation. Multidisciplinary and systematic therapies were needed to improve the poor prognosis of the young NSCLC patients.

背景与目的: 青年(年龄≤40岁)非小细胞肺癌(non-small cell lung cancer, NSCLC)发病率呈上升趋势。本研究旨在分析青年NSCLC的临床病理生理特征、治疗及预后情况。

方法: 对102例资料完整的青年NSCLC患者进行回顾性分析。

结果: 女性所占比例为43.1%,男女比例为1.32:1;29.4%有吸烟史;以腺癌为主,占77.5%;以低分化癌为主,占64.1%;晚期肺癌(Ⅲb期及Ⅳ期)占87.8%。6例接受手术治疗患者的中位复发时间为13.5个月。87例接受一线化疗患者的客观有效率(objective response rate, ORR)为46.0%,疾控率(disease controled rate, DCR)为79.3%,中位肿瘤进展时间(time to progress, TTP)为5.0个月。38例接受表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKI)治疗患者ORR为40%,DCR为65.7%,中位TTP为5.5个月;12例二次或多次TKI治疗患者DCR为66.7%,中位TTP为3.0个月。

结论: 青年NSCLC中位确诊时间长,女性所占比例相对较高,与吸烟的相关性较弱,以分化差的晚期腺癌为主,确诊后应给予积极的综合治疗,但总体预后不佳。

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Carcinoma, Non-Small-Cell Lung / diagnosis*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Female
  • Humans
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / pathology
  • Male
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies
  • Young Adult

Grants and funding

本研究受首都医学发展基金(No.2007-3042)资助